
|

|
Buy Moxifloxacin (Avelox, Vigamox) eye drops and tablets online
How and where to order Avelox, Vigamox (Moxifloxacin Hydrochloride) 400 mg tablets or capsules and opthalmic solution 0.5% 5 ml online:
| Shop: | PHARM X SELLER - 10% discount coupon 918cc60b466a42ba
|
| Sellers: | MOXIFLOXACIN STORES
|
| Prices: | from $2.24 per pill
|
| Forms: | 400 mg tablets, 0.5% 5 ml eye drops
|
| Quantity: | 7-70 pills, 1-10 bottles
|
| Type: | Vigamox brand, Avelox brand and generics
|
| Payment: | Visa, Mastercard, AmEx, Cryptocurrencies
|
| Delivery: | Regular and express mail service
|
| Shipping: | Worldwide, including USA, UK, Europe, Canada, Australia |
Indications and usage:
Moxifloxacin (Avelox) is a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below:
Community acquired pneumonia
Skin and skin structure infections: uncomplicated and complicated
Complicated intra-abdominal infections
Plague
Acute bacterial sinusitis
Acute bacterial exacerbation of chronic bronchitis
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Avelox and other antibacterial drugs. Moxifloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.
Dosage and administration:
The dose of Moxifloxacin (Avelox) is 400 mg every 24 hours for all types of infection:
Community acquired pneumonia: 7–14 days
Uncomplicated skin and skin structure infections (SSSI): 7 days
Complicated SSSI: 7–21 days
Complicated intra-abdominal infections: 5–14 days
Plague: 10–14 days
Acute bacterial sinusitis: 10 days
Acute bacterial exacerbation of chronic bronchitis: 5 days
Dosage forms and strengt:
Avelox tablets: moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin).
Avelox injection: moxifloxacin hydrochloride (equivalent to 400 mg moxifloxacin) in 0.8% sodium chloride solution in a 250 mL flexibag.
Contraindications:
Known hypersensitivity to Avelox (Moxifloxacin) or other quinolones.
Warnings and precautions:
Prolongation of the QT interval and isolated cases of torsade de pointes has been reported. Avoid use in patients with known prolongation, proarrhythmic conditions such as clinically significant bradycardia or acute myocardial ischemia, hypokalemia, hypomagnesemia, and with drugs that prolong the QT interval.
Hypersensitivity and other serious reactions: serious and sometimes fatal reactions, including anaphylactic reactions, may occur after first or subsequent doses of Avelox. Discontinue Moxifloxacin at first sign of skin rash, jaundice or any other sign of hypersensitivity.
Clostridium difficile-associated diarrhea: evaluate if diarrhea occurs.
Adverse reactions, side effects:
Most common adverse reactions of moxifloxacin ( >= 3%) were nausea, diarrhea, headache, and dizziness.
To report suspected adverse reactions of Avelox (Moxifloxacin Hydrochloride) 400 mg, contact Bayer HealthCare Pharmaceuticals Inc. or your local FDA.
Overdosage:
Single oral overdoses up to 2.8 g of Moxifloxacin (Avelox) were not associated with any serious adverse events. In the event of acute overdose, empty the stomach and maintain adequate hydration. Monitor ECG due to the possibility of QT interval prolongation. Carefully observe the patient and give supportive treatment. The administration of activated charcoal as soon as possible after oral overdose may prevent excessive increase of systemic moxifloxacin exposure. About 3% and 9% of the dose of moxifloxacin, as well as about 2% and 4.5% of its glucuronide metabolite are removed by continuous ambulatory peritoneal dialysis and hemodialysis, respectively.
Drug interactions:
Multivalent cation-containing products (including antacids, sucralfate, multivitamins) decreased moxifloxacin absorption. Take Avelox tablet at least 4 hours before or 8 hours after these products.
Warfarin: anticoagulant effect enhanced. Monitor prothrombin time/INR, and bleeding.
Class IA and Class III antiarrhythmics: proarrhythmic effect may be enhanced. Avoid concomitant use.
Antidiabetic agents: carefully monitor blood glucose.
Use in specific populations:
Pregnancy: based on animal data may cause fetal harm.
Nursing mothers: moxifloxacin is excreted in the breast milk of rats. Because of the potential for serious adverse reactions in infants who are nursing from mothers taking this medication.
Pediatric use: safety and effectiveness of this medicine in pediatric patients and adolescents less than 18 years of age have not been established.
Geriatric use: increased risk for severe tendon disorders further increased by concomitant corticosteroid therapy and increased risk of prolongation of the QT interval.
Renal impairment: no dosage adjustment is necessary in patients with renal impairment, including those patients requiring hemodialysis or continuous ambulatory peritoneal dialysis.
Hepatic impairment: no dosage adjustment is recommended for mild, moderate, or severe hepatic insufficiency.
Where to buy moxifloxacin online:
To purchase Vigamox, Avelox (Moxifloxacin Hydrochloride) 400 mg pills and opthalmic solution 0.5% 5 ml from reliable online pharmacies and drugstores at low prices please use resources described above on this webpage.
Here is a list of popular medications containing moxifloxacin hydrochloride as a main active pharmaceutical ingredient; their trade names, forms, doses, companies - manufacturers, distributors, suppliers, researchers and developers:
| Trade name of the drug |
Pharmaceutical forms and doses |
Companies |
| Avelox |
Injectable; Infusion; 400 mg / 250 mlTablets, Film-Coated; Oral; 400 mg |
BayerB & S HealthcareBayHealth Comercializacao de Produtos FarmaceuticosFreseniusGen MedicineMaxxcareMerck |
| Moxicip |
Drops; Ophthalmic; 0.5%Injectable; Infusion; 400 mg / 250 ml, 400 mg / 100 mlOintment; Ophthalmic; 0.5%Tablets, Film-Coated; Oral; 400 mg |
Cipla |
| Moxif |
Injectable; Infusion; 400 mg / 100 mlTablets; Oral; 400 mg |
Torrent Pharmaceuticals |
| Vigamox |
Solution; Ophthalmic; 0.5% |
AlconAlkem PharmaceuticalsMedcor PharmaceuticalsNovartis |

|

|
|

|
Copyright © 2001 - 2024 Respiratory Tract Infection Alert System by Bayer Corporation. All rights reserved.
|
|